All In MedTech

Device Trial Radar · NCT02243033

Phase II Laser Focal Therapy of Prostate Cancer

A Phase II Study to Evaluate Outpatient Magnetic Resonance Image-guided Laser Focal Therapy for Prostate Cancer, a 20-year Survival Study

Last checked: Nov 19, 2026Latest source record: Mar 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

May 2016

Primary completion

May 2036

Study completion Nov 2036

Sponsor

Lead sponsor
HALO DiagnosticsNot on our public-company list
Sponsor type
Industry
First posted
Sep 17, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
Male only, from 45 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Target recruitment: 1000 subjects. The purpose of this research study is to continue to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate oncologic control over 20 years. We hypothesize that laser focal therapy can be used to achieve oncologic control in carefully selected patients. MR uses large magnets to produce pictures of areas/organs inside the body. The laser uses light to heat a target area to try to destroy cancerous cells. The laser system that will be used is called the Visualase® Thermal Therapy System. This system has been used for the treatment of brain, bone (spine), thyroid, and liver cancers. However; this study is the first time this system has been studied for use in the treatment of prostate cancer with a trans-rectal approach. MR-guided biopsies and laser applicator placement will be performed using the Invivo DynaTRIM trans-rectal biopsy guidance system. This system is cleared (approved) by the U.S. Food and Drug Administration (FDA) for such uses.

Conditions

  • Prostate Cancer

Interventions

  • MR-guided laser focal therapyDevice

    Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse eventsTime frame: 1 yr. post treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Desert Medical Imaging

    Indian Wells, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.